Ramy Younes
A5002262686- Liver Disease Diagnosis and Treatment
- Diet, Metabolism, and Disease
- Liver Disease and Transplantation
- Liver Diseases and Immunity
- Hepatitis C virus research
- Diet and metabolism studies
- Pancreatitis Pathology and Treatment
- Hepatocellular Carcinoma Treatment and Prognosis
- Alcohol Consumption and Health Effects
- Diabetes and associated disorders
- Hepatitis B Virus Studies
- Endoplasmic Reticulum Stress and Disease
- Lipid metabolism and disorders
- Liver physiology and pathology
- Pancreatic and Hepatic Oncology Research
- Cardiovascular Disease and Adiposity
- Diabetes Treatment and Management
- Folate and B Vitamins Research
- Systemic Lupus Erythematosus Research
- Hormonal Regulation and Hypertension
- Helicobacter pylori-related gastroenterology studies
- Neuroendocrine Tumor Research Advances
- Cancer, Hypoxia, and Metabolism
- Selenium in Biological Systems
- Lung Cancer Research Studies
King Abdulaziz University
2025
Boehringer Ingelheim (Germany)
2020-2024
Newcastle University
2019-2024
Methodist Hospital
2024
Sorbonne Université
2024
Texas Liver Institute
2024
Inserm
2024
Houston Methodist
2024
The University of Texas Health Science Center at San Antonio
2024
Boehringer Ingelheim (China)
2024
Abstract Hepatocellular carcinoma (HCC) can have viral or non-viral causes 1–5 . Non-alcoholic steatohepatitis (NASH) is an important driver of HCC. Immunotherapy has been approved for treating HCC, but biomarker-based stratification patients optimal response to therapy unmet need 6,7 Here we report the progressive accumulation exhausted, unconventionally activated CD8 + PD1 T cells in NASH-affected livers. In preclinical models NASH-induced therapeutic immunotherapy targeted at programmed...
A 25-gene expression signature associates with progression of fibrosing steatohepatitis in independent NAFLD cohorts.
Nonalcoholic fatty liver disease (NAFLD) affects a quarter of the adult population. A significant subset patients are lean, but their underlying pathophysiology is not well understood.We investigated role bile acids (BAs) and gut microbiome in pathogenesis lean NAFLD. BA fibroblast growth factor (FGF) 19 levels (a surrogate for intestinal farnesoid X receptor [FXR] activity), patatin-like phospholipase domain containing 3 (PNPLA3), transmembrane 6 superfamily member 2 (TM6SF2) variants,...
Objective The full phenotypic expression of non-alcoholic fatty liver disease (NAFLD) in lean subjects is incompletely characterised. We aimed to investigate prevalence, characteristics and long-term prognosis Caucasian with NAFLD. Design study cohort comprises 1339 biopsy-proven NAFLD from four countries (Italy, UK, Spain Australia), stratified into non-lean (body mass index (BMI) </≥25 kg/m 2 ). Liver/non-liver-related events survival free transplantation were recorded during the...
BackgroundDual agonism of glucagon receptor and glucagon-like peptide-1 (GLP-1) may be more effective than GLP-1 alone for treating metabolic dysfunction–associated steatohepatitis (MASH). The efficacy safety survodutide (a dual agonist receptor) in persons with MASH liver fibrosis are unclear.MethodsIn this 48-week, phase 2 trial, we randomly assigned adults biopsy-confirmed stage F1 through F3 a 1:1:1:1 ratio to receive once-weekly subcutaneous injections at dose 2.4, 4.8, or 6.0 mg...
Abstract Metabolic dysfunction-associated steatotic liver disease (MASLD), previously known as non-alcoholic fatty disease, encompasses steatosis and metabolic steatohepatitis (MASH), leading to cirrhosis hepatocellular carcinoma. Preclinical MASLD research is mainly performed in rodents; however, the model that best recapitulates human yet be defined. We conducted a wide-ranging retrospective review (metabolic phenotype, histopathology, transcriptome benchmarked against humans) of murine...
Objective Hyperferritinaemia is associated with liver fibrosis severity in patients metabolic dysfunction-associated steatotic disease (MASLD), but the longitudinal implications have not been thoroughly investigated. We assessed role of serum ferritin predicting long-term outcomes or death. Design evaluated relationship between baseline and events a multicentre cohort 1342 patients. Four survival models considering confounders non-invasive scoring systems were applied repeated five-fold...
There is an unmet need for non-invasive biomarkers in non-alcoholic fatty liver disease (NAFLD) that can diagnose advanced and identify patients suitable clinical trials. The PRO-C3 collagen neo-epitope a putative direct marker of fibrogenesis. We assessed the performance large, well-characterised international NAFLD cohort report development validation 2 novel panels diagnosis fibrosis (F≥3) NAFLD, including simplified score which eliminates online calculators.Plasma levels were determined...
Non-Alcoholic Fatty Liver Disease (NAFLD), a progressive liver disease that is closely associated with obesity, type 2 diabetes, hypertension and dyslipidaemia, represents an increasing global public health challenge. There significant variability in the course: majority exhibit only fat accumulation but minority develop necroinflammatory form of (non-alcoholic steatohepatitis, NASH) may progress to cirrhosis hepatocellular carcinoma. At present our understanding pathogenesis, natural...
Survodutide is a glucagon/glucagon-like peptide-1 receptor dual agonist in development for the treatment of metabolic dysfunction-associated steatohepatitis (MASH). We investigated pharmacokinetic and safety profile survodutide people with cirrhosis.
Surrogate indexes of insulin resistance and sensitivity are widely used in nonalcoholic fatty liver disease (NAFLD), although they have never been validated this population. We aimed to validate the available NAFLD subjects test their ability predict damage also comparison with fibrosis score. were by tracer technique (6,6-D2 -glucose U-(13) C-glucose) basal state during an oral glucose tolerance test. The best-performing independent cohort 145 nondiabetic identify (fibrosis...
Background: Previous research has linked high coffee consumption to an increased risk of metabolic syndrome (MetS). This study aimed assess the relationship between and MetS components among Saudi adults. Methods: A cross-sectional was performed on adults who met at least three criteria for a diagnosis. Data concerning demographics, lifestyle, sleeping patterns, medical health, anthropometric measurements, habitual drinking, lab levels HDL-C, LDL-C, TC, TGs, HbA1c, FBG were collected....
In patients with inflammatory bowel diseases (IBD) undergoing biologic therapy, biomarkers of treatment response are still scarce. This study aimed to evaluate whether serum zonulin, a biomarker intestinal permeability; soluble CD163 (sCD163), macrophage activation marker; and panel cytokines could predict the in IBD. For this purpose, we prospectively enrolled 101 IBD 19 irritable syndrome (IBS) as control group; 60 out underwent biologics. Zonulin, sCD163, were measured at baseline all...